Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
A subgroup of patients with core binding factor acute myeloid leukemias (AML) is characterized by the presence of the fusion gene CBFb-Myh11. At the cytogenetic level, most of these patients are identified by the presence of an inversion of chromosome 16 [inv(16)(p13q22)] and rarely by a translocation t(16;16)(p13;q22). The aim of this study is to describe the natural history of patients with t(16;16) [N = 6] treated at MD Anderson Cancer Center and compared them with a cohort of patients with inv(16)(p13q22) [n = 61]. In patients with t(16;16) the complete remission rate (CR) was 100% when treated with a combination of fludarabine and high-dose cytarabine. Median overall survival (OS) had not been achieved. There was no difference in response or OS or progression free survival between both groups. Presence of additional chromosomal abnormalities and molecular aberrations had no effect on prognosis. In conclusion, and consistent with previous reports, the natural history of patients with t(16:16)(p13;q22) is similar to that of classic patients with inv16 AML and therefore should be treated similarly.
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Alireza
A
Eghtedar
Gautam
G
Borthakur
Farhad
F
Ravandi
Elias
E
Jabbour
Jorge
J
Cortes
Sherry
S
Pierce
Hagop
H
Kantarjian
Guillermo
G
Garcia-Manero
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics / Q000648:ultrastructure*; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012074:Remission Induction; D012189:Retrospective Studies; D014178:Translocation, Genetic; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
C095514:CBFbeta-MYH11 fusion protein; D015514:Oncogene Proteins, Fusion; C471254:inv(16) fusion protein, human; D003561:Cytarabine; D014740:Vidarabine; C024352:fludarabine